Addition of cetuximab to chemotherapy as first-line treatment for KRAS wild-type metastatic colorectal cancer: Pooled analysis of the CRYSTAL and OPUS randomised clinical trials-Reference-Cited by-同舟云学术

Addition of cetuximab to chemotherapy as first-line treatment for KRAS wild-type metastatic colorectal cancer: Pooled analysis of the CRYSTAL and OPUS randomised clinical trials

Published:2012-07 Issue:10 Volume:48 Page:1466-1475
ISSN:0959-8049
Container-title:European Journal of Cancer
language:en
Short-container-title:European Journal of Cancer

Author:

Bokemeyer Carsten,Cutsem Eric Van,Rougier Philippe,Ciardiello Fortunato,Heeger Steffen,Schlichting Michael,Celik Ilhan,Köhne Claus-Henning

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference23 articles.

1. Genetic pathways and mutation profiles of human cancers: site- and exposure-specific patterns;Lea;Carcinogenesis,2007

2. Implications for KRAS status and EGFR-targeted therapies in metastatic CRC;Normanno;Nat Rev Clin Oncol,2009

3. KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab;De Roock;Ann Oncol,2008

4. Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by cetuximab plus chemotherapy;Di Fiore;Br J Cancer,2007

5. KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab;Lievre;J Clin Oncol,2008

Cited by 474 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. First line therapy in stage IV BRAF mutated colorectal cancer;Heliyon;2024-09

2. Impact of primary tumor sidedness and sex on prognosis and anti-epidermal growth factor receptor antibody efficacy in BRAF-mutant metastatic colorectal cancer: a pooled analysis of AIO studies FIRE-1, CIOX, FIRE-3, XELAVIRI, and VOLFI;ESMO Open;2024-09

3. Stereotactic body radiation therapy for colorectal cancer liver metastases;Journal of Gastrointestinal Oncology;2024-08

4. Preoperative chemotherapy response and survival in patients with colorectal cancer peritoneal metastases;Journal of Surgical Oncology;2024-07-16

5. Genome-wide DNA methylation status is a predictor of the efficacy of anti-EGFR antibodies in the second-line treatment of metastatic colorectal cancer: Translational research of the EPIC trial;International Journal of Colorectal Disease;2024-06-11